id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-E-4429-0008,FDA,FDA-2018-E-4429,Patent Term Extension Letter from FDA CDER to U S Patent Trademark Office,Other,Letter(s),2020-07-28T04:00:00Z,2020,7,2020-07-28T04:00:00Z,,2020-07-28T16:17:10Z,,0,0,09000064847acef5
FDA-2018-E-4429-0007,FDA,FDA-2018-E-4429,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2020-06-22T04:00:00Z,2020,6,2020-06-22T04:00:00Z,,2020-06-22T17:52:14Z,,0,0,09000064846ff170
FDA-2018-E-4429-0005,FDA,FDA-2018-E-4429,Determination of Regulatory Review Period for Purposes of Patent Extension; CRYSVITA,Notice,Determinations,2019-11-29T05:00:00Z,2019,11,2019-11-29T05:00:00Z,2020-05-28T03:59:59Z,2020-05-25T01:00:37Z,2019-25821,0,0,09000064841c881c
FDA-2018-E-4429-0004,FDA,FDA-2018-E-4429,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-12T04:00:00Z,2019,9,2019-09-12T04:00:00Z,,2019-09-12T20:24:21Z,,0,0,0900006483f4d7ed
FDA-2018-E-4429-0003,FDA,FDA-2018-E-4429,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-05-13T04:00:00Z,2019,5,2019-05-13T04:00:00Z,,2019-05-13T18:28:16Z,,0,0,0900006483c734b1
FDA-2018-E-4429-0002,FDA,FDA-2018-E-4429,"Patent Extension Application from Woodard, Emhardt, Moriarty, McNett & Henry LLP (on behalf of Michael Econs et al.)",Other,Application,2018-11-19T05:00:00Z,2018,11,2018-11-19T05:00:00Z,,2018-11-19T20:12:41Z,,0,0,09000064838e94b1
FDA-2018-E-4429-0001,FDA,FDA-2018-E-4429,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Application,2018-11-19T05:00:00Z,2018,11,2018-11-19T05:00:00Z,,2018-11-19T20:08:21Z,,0,0,09000064838e9481